StockData
LEGNNasdaqPharmaceutical PreparationsFiscal year ends December 31

Legend Biotech Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 10, 2026
$18.65+0.17 (+0.92%)

Close on Oct 19, 2026

Market cap
$7.23B
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 11, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 11, 2026Before market open$387.50M$0.09$0.16
Q1 FY2026
Ended Mar 31, 2026
May 12, 2026Before market open$305.10M$-0.15$-0.03
Q4 FY2025
Ended Dec 31, 2025
Mar 10, 2026Before market open$306.30M$-0.08$0.01
Q3 FY2025
Ended Sep 30, 2025
Nov 12, 2025Before market open$272.33M$-0.11$-0.05
Q2 FY2025
Ended Jun 30, 2025
Aug 11, 2025Before market open$255.06M$-0.34$0.03
Q1 FY2025
Ended Mar 31, 2025
May 13, 2025Before market open$195.05M$-0.27$-0.07
Q4 FY2024
Ended Dec 31, 2024
Mar 11, 2025Before market open$186.52M$0.07$-0.15
Q3 FY2024
Ended Sep 30, 2024
Nov 12, 2024Before market open$160.21M$-0.34–
Q2 FY2024
Ended Jun 30, 2024
Jul 26, 2024Before market open–––
Q1 FY2024
Ended Mar 31, 2024
May 13, 2024Before market open$93.99M$-0.16–
Q4 FY2023
Ended Dec 31, 2023
Mar 11, 2024Before market open–––

Press releases

Announcements Legend Biotech filed with the SEC